Meghan Breaux
Family · Humble, TXNPI 1548518368
Payments from drug & device makers
Across 252 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$730
- Lilly USA, LLC$587
- GSK$531
- AbbVie$491
- Abbott$385
- Boston Scientific$288
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,579100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 47 | $730 |
| Lilly USA, LLC | 38 | $587 |
| GSK | 27 | $531 |
| AbbVie | 30 | $491 |
| Abbott | 9 | $385 |
| Boston Scientific | 11 | $288 |
| AstraZeneca(2 entities) | 15 | $230 |
| Amgen | 10 | $154 |
| Astellas Pharma US Inc | 7 | $136 |
| Boehringer Ingelheim | 7 | $116 |
| Esperion Therapeutics, Inc. | 6 | $106 |
| Pfizer | 5 | $105 |
| Exact Sciences | 6 | $99 |
| Sanofi-aventis U.S. LLC | 5 | $93 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $89 |
| Phathom Pharmaceuticals, Inc. | 4 | $67 |
| Medtronic | 2 | $46 |
| Imperative Care, Inc | 1 | $35 |
| Sumitomo Pharma America, Inc. | 2 | $32 |
| Viatris Specialty LLC | 1 | $31 |
| Ironwood Pharmaceuticals, Inc | 1 | $24 |
| Novartis | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Insulet Corporation | 1 | $21 |
| 3b Medical, Inc. | 1 | $19 |
| Merck | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Eisai Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,591 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 62 | $81,038 |
| MounjaroTirzepatide | 42 | $49,131 |
| EliquisApixaban | 27 | $39,143 |
| RybelsusSemaglutide | 23 | $27,988 |
| XareltoRivaroxaban | 31 | $26,886 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $14,940 |
| LinzessLinaclotide | 12 | $13,725 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 21 | $13,290 |
| FarxigaDapagliflozin Propanediol | 15 | $12,437 |
| BelsomraSuvorexant | 12 | $4,873 |
| Rosuvastatin Calcium | 232 | $3,671 |
| Losartan Potassium | 235 | $2,648 |
| Atorvastatin Calcium | 253 | $2,243 |
| Omeprazole | 185 | $2,179 |
| Gabapentin | 103 | $1,784 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $730 | $109,02685 claims |
| Lilly USA, LLCMounjaro | $587 | $49,13142 claims |
| PfizerEliquis | $105 | $39,14327 claims |
| Johnson & JohnsonXarelto | $13 | $26,88631 claims |
| GSKTrelegy Ellipta | $531 | $14,94022 claims |
| AbbVieLinzess, Synthroid | $491 | $14,71434 claims |
| Boehringer IngelheimSynjardy Xr | $116 | $13,29021 claims |
| AstraZenecaFarxiga | $230 | $12,43715 claims |
| MerckBelsomra | $19 | $4,87312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.
Other family in Humble
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.